K-ras gene and colorectal cancer therapeutic effect

Abstract

Abstract:K-ras gene is one of oncogenes, which promotes cells growth and differentiation. Ras protein loses the activity of GTP enzyme because of K-ras mutations, and that may cause abnormal growth, differentiation of cells and promote the occurrence of tumor. Patients with colorectal carcinoma that carry mutations in K-ras gene do not benefit from the administration of antiepidermal growth factor receptor (EGFR) polyclonal antibodies. Different solid tumors of colorectal carcinoma have different K-ras mutation rates. Different genotypes of K-ras gene (wildtype or K-ras mutant type) affect significantly on treatment options and prognosis. The efficacy of mutant type patients with antiEGFR antibodies is poor, and the therapeutic effects of 5-FU and FOLFOX are still unclear.

Key words:Colorectal neoplasms,Treatment outcome,K-ras gene

YU Fa-Chang, LI Sheng, NIU Zuo-Xing. K-ras gene and colorectal cancer therapeutic effect[J]. Journal of International Oncology, 2014, 41(3): 214-216.

References

［1］ Navas C, HernándezPorras I, Schuhmacher AJ, et al. EGF receptor signaling is essential for kras oncogenedriven pancreatic ductal adenocarcinoma［J］. Cancer Cell, 2012, 22(3):318330. ［2］ Sebio A, Paré L, Páez D, et al. The LCS6 polymorphism in the binding site of let7 microRNA to the KRAS 3′untranslated region: its role in the efficacy of antiEGFRbased therapy in metastatic colorectal cancer patients［J］. Pharmacogenet Genomics, 2013, 23(3):142147. ［3］ Troiani T, Zappavigna S, Martinelli E, et al. Optimizing treatment of metastatic colorectal cancer patients with antiEGFR antibodies: overcoming the mechanisms of cancer cell resistance［J］. Expert Opin Biol Ther, 2013, 13(2):241255. ［4］ Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic kRAS mutations as a mechanism associated with resistance to EGFRtargeted agents: a systematic review and metaanalysis of studies in advanced nonsmallcell lung cancer and metastatic colorectal cancer［J］. Lancet Oncol, 2008, 9(10):962972. ［5］ Bach LA, Fu P, Yang Z. Insulinlike growth factorbinding protein6 and cancer［J］. Clin Sci (Lond), 2013, 124(4):215229. ［6］ Ramos FJ, Macarulla T, Capdevila J, et al. Understanding the predictive role of Kras for epidermal growth factor receptortargeted therapies in colorectal cancer［J］. Clin Colorectal Cancer, 2008, 7 Suppl 2:S5257. ［7］ Karapetis CS, KhambataFord S, Jonker DJ, et al. Kras mutations and benefit from cetuximab in advanced colorectal cancer［J］. N Engl J Med, 2008, 359(17):17571765. ［8］ De Roock W, Piessevaux H, De Schutter J, et al. KRAS wildtype state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab［J］. Ann Oncol, 2008, 19(3):508515. ［9］ Dempke WC, Heinemann V. Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma［J］. Anticancer Res, 2010, 30(11):46734677. ［10］ Phipps AI, Buchanan DD, Makar KW, et al. KRASmutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers［J］. Br J Cancer, 2013, 108(8):17571764. ［11］ Chen X, Guo X, Zhang H, et al. Role of miR143 targeting KRAS in colorectal tumorigenesis［J］. Oncogene, 2009, 28(10):13851392. ［12］ Borralho PM, Kren BT, Castro RE, et al. MicroRNA143 reduces viability and increases sensitivity to 5fluorouracil in HCT116 human colorectal cancer cells［J］. FEBS J, 2009, 276(22):66896700. ［13］ Bengala C, Bettelli S, Bertolini F, et al. Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy［J］. Br J Cancer, 2010, 103(7):10191024. ［14］ Van Cutsem E, Khne CH, Lng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as firstline treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status［J］. J Clin Oncol, 2011, 29(15):20112019. ［15］ Bokemeyer C, Bondarenko I, Hartmann JT, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX4 as firstline treatment for metastatic colorectal cancer: the OPUS study［J］. Ann Oncol, 2011, 22(7):15351546. ［16］ Commisso C, Davidson SM, SoydanerAzeloglu RG, et al. Macropinocytosis of protein is an amino acid supply route in Rastransformed cells［J］. Nature, 2013, 497(7451):633637. ［17］ Chang MH, Lee IK, Si Y, et al. Clinical impact of Kras mutation in colorectal cancer patients treated with adjuvant FOLFOX［J］. Cancer Chemother Pharmacol, 2011, 68(2):317323.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[3]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[4]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[5]	Wang Kun, Zhou Zhongxin, Zang Qiwei.Predictive value of serum TGF-β1 and VEGF levels in patients with non-small cell lung cancer after single-port thoracoscopic radical resection[J]. Journal of International Oncology, 2024, 51(4): 198-203.
[6]	Yan Aiting, Wang Cuizhu, Liu Chungui, Lu Xiaomin.Clinical efficacy and safety of camrelizumab and sintilimab in the treatment of advanced non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(3): 137-142.
[7]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan.Research progress on the histopathological growth patterns of colorectal liver metastasis[J]. Journal of International Oncology, 2024, 51(2): 114-118.
[8]	Jiang Xi, Wu Yongcun, Liang Yan, Chu Li, Duan Yingxin, Wang Lijun, Huo Junjie.Impact of pembrolizumab combined with chemotherapy on angiogenesis and circulating endothelial cells in patients with advanced non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(2): 89-94.
[9]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei.Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients[J]. Journal of International Oncology, 2024, 51(1): 37-42.
[10]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong.Expression and clinical significance of ASB6 in colorectal cancer tissues[J]. Journal of International Oncology, 2023, 50(8): 470-474.
[11]	Chen Zhuo, Tao Jun, Chen Lin, Ke Jing.Value of detection of peripheral blood miR-194 combined with fecal miR-143 in the clinical screening of colorectal cancer[J]. Journal of International Oncology, 2023, 50(5): 268-273.
[12]	Zhou Ting, Xu Shaohua, Mei Lin.Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer[J]. Journal of International Oncology, 2023, 50(3): 144-149.
[13]	Huang Zhen, Zhang Caiyutian, Ke Shaobo, Shi Wei, Zhao Wensi, Chen Yongshun.Construction of postoperative prognosis model for patients with colorectal cancer[J]. Journal of International Oncology, 2023, 50(3): 157-163.
[14]	Cao Mengqing, Xu Zhiyong, Shi Yuting, Wang Kai.Role of tertiary lymphoid structures in tumor immune microenvironment regulation and anti-tumor therapy[J]. Journal of International Oncology, 2023, 50(3): 169-173.
[15]	Xu Liangfu, Li Yuanfei.Research progress on tumor microenvironment and immune combination therapy of MSS colorectal cancer[J]. Journal of International Oncology, 2023, 50(3): 186-190.